U.S. Fibromyalgia Treatment Market - Databook 2025 to 2034

The U.S. fibromyalgia treatment market size accounted for USD 849 million in 2024 and is predicted to touch around USD 1,274 million by 2034, growing at a CAGR of 4.14% from 2025 to 2034.

Highlights of the U.S. Fibromyalgia Treatment Market

• By treatment type, the medications segment held a dominant presence in the U.S. fibromyalgia treatment market in 2024.
• By treatment type, the therapies segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By distribution channel, the retail pharmacies segment enjoyed a prominent position in the U.S. fibromyalgia treatment market in 2024.
• By distribution channel, the hospital pharmacies segment is projected to expand rapidly in the market in the coming years.

Industry Valuation and Growth Rate Projection

There is no cure for fibromyalgia, but doctors and other healthcare providers can help manage and treat the symptoms. Fibromyalgia treatment generally includes a combination of psychological and behavioural therapy, medications, and self-management approaches like physical exercise and other movement therapies like tai chi or yoga. The U.S. fibromyalgia treatment market growth is driven by increased spending in research and development, advancements in biomarker and genetic research, and rising demand for early diagnosis and intervention.

The U.S. fibromyalgia treatment market includes a wide range of applications that aim to ease the symptoms and improve quality of life. The main treatments are medicines, taking medicines, and therapies. The treatment goals include managing comorbid medical & mental health conditions, improving patient self-management, maximizing cognitive & physical functions, and mitigating cognitive & physical functions.

Market Trends

• Increasing spending on research and development: Research and development (R&D) can lead to breakthroughs that can drive well-being and profits for consumers. R&D can lead to advancements in business in terms of new products and services. These innovations can result in lower costs and greater profits. Government-funded R&D produces long-term productivity profits.
• Innovation in biomarker and genetic research: Biomarkers drive innovation in various healthcare domains. They allow early intervention strategies, enhance treatment response assessment, and improve disease monitoring. Benefits of using genetic technology include faster-growing plants & animals, and an increased supply of food with longer shelf life & reduced cost.
• Demand for effective treatment options: Treatment effectiveness has the ability of many interventions targeting cognition, affect, biology, behavior, or interpersonal processes to effectively enhance psychological symptoms, distress, and functioning in individuals with psychological disorders.

Restraints

• Healthcare costs associated with fibromyalgia therapy for chronic conditions: High healthcare costs are associated with fibromyalgia therapy for chronic conditions can hinder the growth of the U.S. fibromyalgia treatment market. Physician services and hospital services are two of the largest categories of health spending. From 2014 to 2023, both saw an average annual growth rate of 5.3%.
• High R&D costs and lengthy approval timelines for new drugs targeting fibromyalgia: Companies in the pharmaceutical, healthcare, technological, and industrial sectors generally have the highest levels of R&D expenses. R&D costs may be high during the early stages of business as we work on a prototype or create a minimally viable product (MVP). Learning how to better evaluate what you are spending on R&D and why.

Opportunity

Growth in clinical trial investments: Clinical trials are critical tools that help us better understand and enhance human health and healthcare. They enable us to evaluate new medical interventions, including lifestyle modifications, vaccines, devices, and drugs, and identify those that are most likely to benefit patients.

Recent Developments in the U.S. Fibromyalgia Treatment Market:

• In April 2025, TONIX ONE, a comprehensive digital platform for migraine management, was launched by Tonix Pharmaceuticals (TNXP). The platform integrates partnerships with Blink Health, ProModRx, UpScript Telemedicine, and a leading migraine diary app to streamline patient care from symptom tracking to prescription fulfillment. New Digital Platform TONIX ONE Revolutionizes Migraine Management | TNXP Stock News
• In November 2022, the presentation of research supporting the use of its digital therapeutic to deliver behavioral therapy for fibromyalgia management was announced by a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, Swing Therapeutics.